Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$82 Mln
P/E Ratio
--
P/B Ratio
1.64
Industry P/E
--
Debt to Equity
0.94
ROE
-1.56 %
ROCE
-116.17 %
Div. Yield
0 %
Book Value
0.79
EPS
-3.21
CFO
$-465.24 Mln
EBITDA
$-797.56 Mln
Net Profit
$-777.98 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
IGM Biosciences (IGMS)
| -78.40 | 4.76 | -21.89 | -83.42 | -58.31 | -52.83 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
IGM Biosciences (IGMS)
| -26.29 | -51.15 | -42.00 | -66.78 | 131.37 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc.... in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. Read more
CEO, President & Director
Mr. Fred M. Schwarzer J.D.
CEO, President & Director
Mr. Fred M. Schwarzer J.D.
Headquarters
Mountain View, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of IGM Biosciences Inc (IGMS) stood at $ 266 Mln as on 31-Dec-24
The share price of IGM Biosciences Inc (IGMS) is $1.32 (NASDAQ) as of 25-Apr-2025 16:02 EDT. IGM Biosciences Inc (IGMS) has given a return of -58.31% in the last 3 years.
IGM Biosciences Inc (IGMS) has a market capitalisation of $ 82 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of IGM Biosciences Inc (IGMS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the IGM Biosciences Inc (IGMS) and enter the required number of quantities and click on buy to purchase the shares of IGM Biosciences Inc (IGMS).
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
The CEO & director of Mr. Fred M. Schwarzer J.D.. is IGM Biosciences Inc (IGMS), and CFO & Sr. VP is Mr. Fred M. Schwarzer J.D..
There is no promoter pledging in IGM Biosciences Inc (IGMS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| IGM Biosciences Inc. (IGMS) | Ratios |
|---|---|
|
Return on equity(%)
|
-155.76
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-7308.51
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of IGM Biosciences Inc (IGMS) was $0 Mln.
$-0.06
(
